Androgen regulation of epithelial-mesenchymal transition in prostate tumorigenesis

Expert Review of Endocrinology and Metabolism

Volumn 6, Issue 3, 2011, Pages 469-482

  Matuszak, Emily A ^a   Kyprianou, Natasha ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

androgen axis; androgen receptor; cadherins; EMT; metastasis; prostate tumor progression; stem cells; TGF ; tumor microenvironment; vimentin; ZEB1 2

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BETA CATENIN; CADHERIN; HOMEODOMAIN PROTEIN; MATRIX METALLOPROTEINASE; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR SOX; TRANSCRIPTION FACTOR TWIST; TRANSFORMING GROWTH FACTOR BETA; VIMENTIN; ZINC FINGER PROTEIN;

CANCER GROWTH; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL ADHESION; CELL DIFFERENTIATION; CELL MIGRATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; METASTASIS; PATHOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; TUMOR MICROENVIRONMENT;

EID: 79956067762     PISSN: 17446651     EISSN: 17448417     Source Type: Journal    
DOI: 10.1586/eem.11.32     Document Type: Review

References (120)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics 2010. CA Cancer J. Clin. 60(5), 227-300 (2010).
2. American Cancer Society. Cancer Facts and epithelial-mesenchymal transitions 2010. American Cancer Society, GA, USA (2010).
3. Taichman RS, Loberg RD, Mehra R, et al. The evolving biology and treatment of prostate cancer. J. Clin. Invest. 117(9), 2351-2361 (2007). (Pubitemid 47494332)
4. Brooke GN, Bevan CL. The role of androgen receptor mutations in prostate cancer progression. Curr. Genomics 10(1), 18-25 (2009).
5. Schaeffer EM, Marchionni L, Huang Z, et al. Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer. Oncogene 27(57), 7180-7191 (2008).
6. Dehm SM, Tindall DJ. Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol. Endocrinol. 21(12), 2855-2863 (2007). (Pubitemid 350223500)
7. Harris WP, Mostaghel EA, Nelson PS, et al. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat. Clin. Pract. Urol. 6(2), 76-85 (2009).
8. Risbridger GP, Davis ID, Birrell SN, Tilley WD. Breast and prostate cancer: more similar than different. Nat. Rev. Cancer 10(3), 205-212 (2010).
9. Nieto M, Finn S, Loda M, Hahn WC. Prostate cancer: re-focusing on androgen receptor signaling. Int. J. Biochem. Cell Biol. 39(9), 1562-1568 (2007). (Pubitemid 47088307)
10. Mellado B, Codony J, Ribal MJ, Visa L, Gascan P. Molecular biology of androgenindependent prostate cancer: the role of the androgen receptor pathway. Clin. Transl. Oncol. 11(1), 5-10 (2009).
11. Wikström P, Ohlson N, Stattin P, Bergh A. Nuclear androgen receptors recur in the epithelial and stromal compartments of malignant and non-malignant human prostate tissue several months after castration therapy. Prostate 67(12), 1277-1284 (2007). (Pubitemid 47435775)
12. Wang Q, Li W, Zhang Y, et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138(2), 245-256 (2009).
13. Zhu ML, Kyprianou N. Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells. FASEB J. 24, 769-777 (2010).
14. Greenburg G, Hay ED. Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells. J. Cell Biol. 95(1), 333-339 (1982). (Pubitemid 13197104)
15. Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J. Clin. Invest. 119(6), 1438-1449 (2009).
16. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell 14(6), 818-829 (2008). (Pubitemid 351757205)
17. Kalluri R, Weinberg R. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119(6), 1420-1428 (2009).
18. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 139(5), 871-890 (2009).
19. Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J. Clin. Invest. 119(6), 1417-1419 (2009).
20. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 9(4), 265-273 (2009).
21. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 9(4), 239-252 (2009).
22. Moustakas A, Hledin CH. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci. 98(10), 1512-1520 (2007). (Pubitemid 47308444)
23. Moreno-Bueno G, Portillo F, Cano A. Transcriptional regulation of cell polarity in EMT and cancer. Oncogene 27(55), 6958-6969 (2008).
24. Tse J, Kalluri R. Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J. Cell Biochem. 101(4), 816-829 (2007). (Pubitemid 47040864)
25. Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res. 70(14), 5649-5669 (2010).
26. Geiger TR, Peeper DS. Metastasis mechanisms. Biochim. Biophys. Acta 1796(2), 293-308 (2009).
27. Iwatsuki M, Mimori K, Yokobori T, et al. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 101(2), 293-299 (2010).
28. Voulgari A, Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim. Biophys. Acta 1796(2), 75-90 (2009).
29. Chaffer CL, Thompson EW, Williams ED. Mesenchymal to epithelial transition in development and disease. Cells Tissues Organs 185(1-3), 7-19 (2007). (Pubitemid 46956838)
30. Hara T, Miyazaki H, Lee A, Tran CP, Reiter RE. Androgen receptor and invasion in prostate cancer. Cancer Res. 68(4), 1128-1135 (2008). (Pubitemid 351272231)
31. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 68(10), 3645-3654 (2008).
32. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene 27(55), 6920-6929 (2008).
33. Makrilia N, Kollias A, Manolopoulos L, Syrigos K. Cell adhesion molecules: role and clinical significance in cancer. Cancer Invest. 27(10), 1023-1037 (2009).
34. Zeisberg M, Neilson E. Biomarkers for epithelial-mesenchymal transitions. J. Clin. Invest. 119(6), 1429-1437 (2009).
35. Liu YN, Liu Y, Lee HJ, Hsu YH, Chen JH. Activated androgen receptor downregulates E-cadherin gene expression and promotes tumor metastasis. Mol. Cell Biol. 28(23), 7096-7108 (2008).
36. Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y, Johnson KR. Cadherin switching. J. Cell Sci. 121(Pt 6), 727-735 (2008). (Pubitemid 351578108)
37. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin. Cancer Res. 13(23), 7003-7011 (2007). (Pubitemid 350276881)
38. Harris TJ, Tepass U. Adherens junctions: from molecules to morphogenesis. Nat. Rev. Mol. Cell Bio. 11(7), 502-514 (2010).
39. Jaggi M, Nazemi T, Abrahams NA, et al. N-cadherin switching occurs in high Gleason grade prostate cancer. Prostate 66(2), 193-199 (2006). (Pubitemid 43191240)
40. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 28(1-2), 15-33 (2009).
41. Jennbacken K, Tešan T, Wang W, Gustavsson H, Damber JE, Welén K. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer. Endocr. Relat. Cancer 17(2), 469-479 (2010).
42. Tanaka H, Kono E, Tran CP, et al. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat. Med. 16(12), 1414-1420 (2010).
43. Li H, Price DK, William D, Figg WD. ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancer. Anticancer Drugs 18(5), 563-568 (2007). (Pubitemid 46597411)
44. Blaschuk OW, Devemy E. Cadherins as novel targets for anti-cancer therapy. Eur. J. Pharmacol. 625(1-3), 195-198 (2009).
45. Chu K, Cheng CJ, Ye X, et al. Cadherin-11 promotes the metastasis of prostate cancer cells to bone. Mol. Cancer Res. 6(8), 1259-1267 (2008).
46. Lee YC, Cheng CJ, Huang M, et al. Androgen depletion up-regulated cadherin-11 expression in prostate cancer. J. Pathol. 221(1), 68-76 (2010).
47. Niu YN, Xia SJ. Stroma-epithelium crosstalk in prostate cancer. Asian J. Androl. 11(1), 28-35 (2009).
48. Robinson DR, Zylstra CR, Williams BO. Wnt signaling and prostate cancer. Curr. Drug Targets 9(7), 571-780 (2008).
49. Li Y, Wang L, Zhang M, et al. LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion. Cancer Res. 69(8), 3332-3338 (2009).
50. Wang G, Wang J, Sadar MD. Crosstalk between the androgen receptor and b-catenin in castrate-resistant prostate cancer. Cancer Res. 68(23), 9918-9927 (2008).
51. Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, b-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 28(1-2), 151-166 (2009).
52. Polette M, Mestdagt M, Bindels S, et al. b-Catenin and ZO-1: shuttle molecules involved in tumor invasion-associated epithelial-mesenchymal transition processes. Cells Tissues Organs 185(1-3), 61-65 (2007). (Pubitemid 46956844)
53. Whitaker HC, Girling J, Warren AY, Leung H, Mills IG, Neal DE. Alterations in b-catenin expression and localization in prostate cancer. Prostate 68(11), 1196-1205 (2008).
54. Saha B, Arase A, Imam SS, et al. Overexpression of E-cadherin and b-catenin proteins in metastatic prostate cancer cells in bone. Prostate 68(1), 78-84 (2008).
55. Schweizer L, Rizzo CA, Spires TE, et al. The androgen receptor can signal through Wnt/b-catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens. BMC Cell Biol. 9, 4 (2008).
56. Heebøll S, Borre M, Ottosen PD, Dyrskjøt L, Torben Fa, Tørring N. Snail1 is over-expressed in prostate cancer. APMIS 117(3), 196-204 (2009).
57. Hou Z, Peng H, White DE, et al. 14-13-3 binding sites in the snail protein are essential for snail mediated transcriptional repression and epithelial-mesenchymal differentiation. Cancer Res. 70(11), 4385-4393 (2010).
58. Du C, Zhang C, Hassan S, Biswas MH, Balaji KC. Protein kinase D1 suppresses epithelial-to-mesenchymal transition through phosphorylation of snail. Cancer Res. 70(20), 7810-7819 (2010).
59. Ota I, Li XY, Hu Y, Weiss SJ. Induction of a MT1-MMP and MT2-MMP-dependent basement membrane transmigration program in cancer cells by Snail1. Proc. Natl Acad. Sci. USA 106(48), 20318-20323 (2009).
60. Baygi EM, Soheili ZS, Schmitz I, Sameie S, Schulz WA. Snail regulated cell survival and inhibits senescence in human metastatic prostate cancer cell lines. Cell Biol. Toxicol. 26(6), 553-567 (2010).
61. Olmeda D, Jordá M, Peinado H, Fabra A, Cano A. Snail silencing effectively suppresses tumor growth and invasiveness. Oncogene 26(13), 1862-1874 (2007). (Pubitemid 46474642)
62. Cakouros D, Raices RM, Gronthos S, Glackin CA. Twist-ing cell fate: mechanistic insights into the role of twist in lineage specification/ differentiation and tumorigenesis. J. Cell Biochem. 110(6), 1288-1298 (2010).
63. Ansieau S, Morel AP, Hinkal G, Bastid J, Puisieux A. TWISTing an embryonic transcription factor into an oncoprotein. Oncogene 29(22), 3173-3184 (2010).
64. Yuen HF, Chua CW, Chan YP, Wong YC, Wang X, Chan KW. Significance of TWIST and E-cadherin expression in the metastatic progression of prostatic cancer. Histopathology 50(5), 648-658 (2007). (Pubitemid 46495834)
65. Shiota M, Yokomizo A, Tada Y, et al. Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression. Oncogene 29(2), 237-250 (2010).
66. Lefebvre V, Dumitriu B, Penzo-Méndez A, Han Y, Pallavi B. Control of cell fate and differentiation by sry-related highmobilitygroup box (Sox) transcription factors. Int. J. Cell Biol. 39(12), 2195-2214 (2007). (Pubitemid 47484275)
67. Wang H, McKnight NC, Zhang T, Lu ML, Balk SP, Yuan X. SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells. Cancer Res. 67(2), 528-536 (2007). (Pubitemid 46192189)
68. Wang H, Leav I, Ibaragi S, et al. SOX9 is expressed in human fetal prostate epithelium and enhances prostate cancer invasion. Cancer Res. 68(6), 1625-1630 (2008). (Pubitemid 351416545)
69. Thomsen MK, Butler CM, Shen MM, Swain A. Sox9 is required for prostate development. Dev. Biol. 316(2), 302-311 (2008).
70. Peinado H, Olmeda D, Cano A. Snail, ZEB and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat. Rev. Cancer 7(6), 415-428 (2007). (Pubitemid 46809165)
71. Brabletz S, Brabletz T. The ZEB/miR-200 feedback loop -a motor of cellular plasticity in development and cancer. EMBO Rep. 11(9), 670-677 (2010).
72. Vandewalle C, Van Roy F, Berx G. The role of the ZEB family of transcription factors in development and disease. Cell Mol. Life Sci. 66(5), 773-787 (2009).
73. Spaderna S, Schmalhofer O, Wahlbuhl M, et al. The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res. 68(2), 537-544 (2008). (Pubitemid 351380082)
74. Aigner K, Dampier B, Descovich L, et al. The transcription factor ZEB1 (DEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene 26(49), 6979-6988 (2007). (Pubitemid 350014612)
75. Graham T, Zhau H, Odero-Marah V, et al. Insulin-like growth factor-1-dependent up-regulation of ZEB1 drives epithelial-tomesenchymal transition in human prostate cancer cells. Cancer Res. 68(7), 2479-2488 (2008). (Pubitemid 351521824)
76. Anose BM, LaGoo L, Schwendinger J. Characterization of androgen regulation of ZEB-1 and PSA in 22RV1 prostate cancer cells. Adv. Exp. Med. Biol. 617, 541-546 (2008).
77. Drake JM, Strohbehn G, Moreland JG, Henry MD. ZEB1 enhances transendothelial migration and represses the epithelial phenotype of prostate cancer cells. Mol. Biol. Cell 20(8), 2207-2217 (2009).
78. Lui Y, El-Naggar S, Darling DS, Higashi Y, Dean DC. Zeb1 links epithelialmesenchymal transition and cellular senescence. Development 135(3), 579-588 (2008).
79. Das S, Becker BN, Hoffmann FM, Mertz JE. Complete reversal of epithelial to mesenchymal transition requires inhibition of both ZEB expression and the Rho pathway. BMC Cell Biol. 10, 94 (2009).
80. Miyazono K. Transforming growth factor-b signaling in epithelial-mesenchymal transition and progression of cancer. Proc. Jpn Acad. Ser. 85(8), 314-323 (2009).
81. Spoelstra NS, Manning NG, Higashi Y, et al. The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers. Cancer Res. 66(7), 3893-3902 (2006).
82. Graham TR, Yacoub R, Taliaferro-Smith L, et al. Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells. Breast Cancer Res. Treat. 123(1), 139-147 (2010).
83. Strover DG, Bierie B, Moses HL. A delicate balance: TGF-b and the tumor microenvironment. J. Cell Biochem. 101(4), 851-861 (2007). (Pubitemid 47040867)
84. Laconi E. The evolving concept of tumor microenvironments. Bioessays 29(8), 738-744 (2007). (Pubitemid 47204279)
85. Yang F, Tuxhorn JA, Ressler SJ, McAlhany SJ, Dang TD, Rowley DR. Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res. 65(19), 8887-8895 (2005). (Pubitemid 41377378)
86. Derynck R, Akhurst RJ, Balmain A. TGF-b signaling in tumor suppression and cancer progression. Nat. Genet. 29(2), 117-129 (2001). (Pubitemid 32952643)
87. Zhu B, Kyprianou N. TGF-b signaling in prostate cancer. Cancer Treat. Res. 126, 157-173 (2005).
88. Prins GS, Putz O. Molecular signaling pathways that regulate prostate gland development. Differentiation 76(6), 641-659 (2008). (Pubitemid 352032742)
89. Ivanovic V, Melman A, Davis-Joseph B, Valcic M, Gelieber J. Elevated plasma levels of TGF-b in patients with invasive cancer. Nat. Med. 1(4), 282-284 (1995).
90. Morton DM, Barrack ER. Modulation of transforming growth factor-b effects on prostate cancer cell proliferation by growth factors and extracellular matrix. Cancer Res. 55(12), 2596-2602 (1995).
91. Joesting MS, Perrin S, Elenbaas B, et al. Identification of SFRP1 as a candidate mediator of stromal-to-epithelial signaling in prostate cancer. Cancer Res. 65(22), 10423-10430 (2005). (Pubitemid 41743736)
92. Ayala GE, Dai H, Tahir SA, et al. Stromal antiapototic paracrine loop in perineural invasion of prostatic carcinoma. Cancer Res. 66(10), 5159-5164 (2006). (Pubitemid 43844938)
93. Pu H, Collazo J, Jones E, et al. Dysfunctional transforming growth factor-b receptor II accelerates prostate tumorigenesis in the TRAMP mouse model. Cancer Res. 69(18), 7366-7374 (2009).
94. Cano P, Godoy A, Escamilla R, Dhir R, Onate SA. Stromal-epithelial cell interactions and androgen receptor-coregulator recruitment is altered in the tissue microenvironment of prostate cancer. Cancer Res. 67(2), 511-519 (2007). (Pubitemid 46192187)
95. Jones E, Pu H, Kyprianou N. Targeting TGF-b in prostate cancer: therapeutic possibilities during tumor progression. Expert Opin Ther. Targets 13(2), 227-234 (2009).
96. Dutsch-Wicherek M. RCAS1, MT, and vimentin as potential markers of tumor microenvironment remodeling. Am. J. Reprod. Immunol. 63(3), 181-188 (2010).
97. Zhao Y, Yan Q, Long X. Chen X, Wang Y. Vimentin affects the mobility and invasiveness of prostate cancer cells. Cell Biochem. Funct. 26(5), 571-577 (2008).
98. Mendez MG, Kojima SI, Goldman RD. Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. FASEB J. 24(6), 1838-1851 (2010).
99. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141(1), 52-67 (2010).
100. Wilson TJ, Singh RK. Proteases as modulators of tumor-stromal interaction: primary tumors to bone metastases. Biochim. Biophys. Acta 1785(2), 85-95 (2008).
101. Orlichenko LS, Radisky DC. Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development. Clin. Exp. Metastasis 25(6), 593-600 (2008).
102. Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 278(1), 16-27 (2010).
103. Escaff S, Fernández JM, González LO, et al. Study of matrix metalloproteinases and their inhibitors in prostate cancer. Br. J. Cancer 102(5), 922-929 (2010).
104. Lawrence M, Veveri-Lowe T, Whitbread A, Nicol D, Clements J. Epithelial-mesenchymal transitions in prostate cancer and the potential role of kallikrein serine proteases. Cells Tissues Organs 185(1-3), 111-115 (2007). (Pubitemid 46956851)
105. Kaarbø M, Klokk TI, Saatcioglu FS. Androgen signaling and its interaction with other signaling pathways in prostate cancer. Bioessays 29(12), 1227-1238 (2007). (Pubitemid 350221791)
106. Blum R, Gupta R, Burger PE, et al. Molecular signatures of the primitive prostate stem cell niche reveal novel mesenchymal-epithelial signaling pathways. PLoS One 5(9), e13024 (2010).
107. Taylor RA, Risbridger GP. Prostatic tumor stroma: a key player in cancer progression. Curr. Cancer Drug Targets 8, 490-497 (2008).
108. Wang X, Kruithof-de Julio M, Economides KD, et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 461(7263), 495-500 (2009).
109. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 8(10), 755-768 (2008).
110. Kong D, Banerjee S, Ahmad A, et al. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One 5(8), e12445 (2010).
111. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4), 704-715 (2008). (Pubitemid 351636299)
112. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29(34), 4741-4751 (2010).
113. Klarmann GJ, Hurt EM, Mathews LA, et al. Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin. Exp. Metastasis 26, 433-446 (2009).
114. Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA. MicroRNAs -the micro steering wheel of tumor metastases. Nat. Rev. Cancer 9(4), 293-302 (2009).
115. Liu C, Kelnar K, Liu B, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat. Med. 17(2), 211-216 (2011).
116. Zhang H, Li Y, Lai M. The microRNA network and tumor metastasis. Oncogene 29, 937-948 (2010).
117. Dykxhoorn DM. MicroRNAs and metastasis: little RNAs go a long way. Cancer Res. 70(16), 6401-6406 (2010).
118. Tessel MA, Krett NL, Rosen ST. Steroid receptor and microRNA regulation in cancer. Curr. Opin. Oncol. 22(6), 592-597 (2010).
119. Ostling P, Leivonen SK, Aakula A, et al. Systematic analysis of micrornas targeting the androgen receptor in prostate cancer cells. Cancer Res. 71(5), 1956-1967 (2011).
120. De Wever O, Pauwels P, De Craene B, et al. Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front. Histochem. Cell Biol. 130(3), 481-494 (2008).